18 and older, any sex, with Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Fraction of Patients (n=3) for Whom a sdAb Could be Generated That Binds to the Idiotype of the Paraprotein.Primary· Within 2 years after study completion
Reporting of the relative amount of patients for whom such sdAb could be successfully obtained
Group
Value
95% CI
Patients With a Clinically Suspected or Pathologically Confirmed Multiple Myeloma.
2
Amount of Paraprotein-targeting sdAbs Generated Per PatientPrimary· Within 2 years after study completion
Absolute amount of unique sdAbs obtained per patient
number of different SdAb for subject 1
Group
Value
95% CI
Patients With a Clinically Suspected or Pathologically Confirmed Multiple Myeloma.
14
number of different SdAb for subject 2
Group
Value
95% CI
Patients With a Clinically Suspected or Pathologically Confirmed Multiple Myeloma.
0
number of different SdAb for subject 5
Group
Value
95% CI
Patients With a Clinically Suspected or Pathologically Confirmed Multiple Myeloma.
20
Sponsor's own description
This study aims to show that antiidiotypic sdAb are a new, sensitive, specific and non-invasive tool for imaging and therapeutic purposes and provides a rationale for their clinical evaluation as a personalized treatment option for MM patients expressing surface paraprotein.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07200102 — Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma
· Phase 1
· recruiting
NCT07340853 — CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
· Phase 1
· recruiting
NCT07454382 — A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma
· Phase 2
· recruiting
NCT07266441 — A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
· Phase 2
· recruiting
NCT07258511 — A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With
· Phase 3
· recruiting
Other Universitair Ziekenhuis Brussel trials
Trials by the same sponsor.
NCT07536230 — Deep Learning Framework for Continuous Depth of Anesthesia Forecasting
· not yet recruiting
NCT07533968 — The Aim of This Study is to Gain Insight Into the Occurrence of Irritable Bowel Symptoms During Ovarian Stimulation in I
· NA
· not yet recruiting
NCT07289984 — Correlation Between Diagnostic Nerve Block Response and Cryoneurolysis Outcome in Chronic Musculoskeletal Disorders and
· NA
· not yet recruiting
NCT06923813 — Assessment of Nutrient Absorption in Enterally Fed Post-intensive Care Unit Patients Using Bomb Calorimetry: do the Calo
· NA
· recruiting
NCT07401004 — Effect of Blink-Based Training on Cancer Detection in Colorectal Polyp Images by Medical Students/Non GI-trainees
· NA
· completed
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Universitair Ziekenhuis Brussel
Last refreshed: 1 December 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03956615.